News Release

Traditional Chinese medicine is effective for recurrent respiratory infections in children, says pediatric investigation study

Clinical trial shows that the traditional Chinese medicine, Yupingfeng, is as effective as allopathic drugs in treating recurrent respiratory tract infections in children

Peer-Reviewed Publication

Cactus Communications

Yupingfeng, a traditional Chinese medicine is a safe and effective treatment for recurrent respiratory tract infections

image: Based on the results of a randomized, double-blind, clinical trial, Yupingfeng granules are not inferior to allopathic pidotimod as a treatment for pediatric recurrent respiratory tract infections. view more 

Credit: Pediatric Investigation

The practice of traditional Chinese medicine (TCM) commenced as early as 14th century BC, and it has now become an active hotspot of research. Despite this, TCM is frequently viewed with great skepticism in the western world and equated to a pseudoscience. This is often because the effects of TCMs are poorly understood and few studies have documented their efficacy and safety via randomized controlled clinical trials (RCTs). One such TCM is Yupingfeng (YPF, 玉屏风)—a patented formula available as compounded granules that includes Astragali radix (Huangqi), Atractylodis macrocephalae rhizoma (Baizhu), and Saposhnikoviae radix (Fangfeng)—which is often used in China to treat recurrent respiratory tract infections (RRTIs) in children. Although YPF is known to improve immune function, the evidence for its efficacy against pediatric RRTIs has remained weak.

To address this gap, a large group of researchers from China conducted a multicenter  RCT to evaluate the safety and efficacy of YPF in children with RRTIs. The results from this double-blind RCT were first published on June 2, 2022, in the journal Pediatric Investigation. Prof. Kunling Shen, who spearheaded this study, explains, We wanted to perform a rigorous investigation to understand the therapeutic benefits of YPF. This is why we conducted a large scale RCT, the gold standard of clinical studies, and enrolled patients not from a single center but from multiple hospitals.”

This study enrolled 351 children with RRTIs (aged 2–6 years) who were randomly divided into three groups. While the first group received YPF, the second group received pidotimod—a conventional allopathic drug used for RRTI treatment since the ‘90s. The third group only received placebo treatment. To remove as much bias as possible, neither the patients nor their doctors were made aware of the treatment being administered. Following 8 weeks of treatment, the investigators examined the proportion of patients in whom the frequency of infections reduced to average levels (i.e., RRTIs returning to normal standard). They also examined the reduction in RRTI events and safety in each group.

During 52 weeks of follow-up after the treatment, the proportion of RRTIs returning to normal standard was only 39% in the placebo group. However, it was much better at 73% and 67% in the YPF and pidotimod groups, respectively. These two groups also showed a substantially greater reduction in RRTI events during the follow-up. Moreover, the safety profile was similar across all three groups. Together, the findings indicated that YPF was not inferior to pidotimod in treating RRTIs and did not have any safety issues either. YPF also costs less than pidotimod and was thus a more economically feasible option.

The strength of our study lies in its rigorous design. It is the largest multicenter study to prove that YPF, a TCM, can be as effective as an allopathic drug in treating RRTIs. It is a major step forward in sharing the benefits of TCM with the world,” comments Prof. Rong Ma, who led this study along with Prof. Shen.

Indeed, this study has cemented the value of YPF in treating RRTIs, which are common among children in China and in other parts of the world. It shows that TCMs can be as effective and safe as allopathic drugs, even though we may not fully understand the biological mechanisms underlying their effects. Dr. Julian L. Allen, an Associate Editor at Pediatric Investigation, wrote an editorial and said Just because we don’t understand how a drug works, it doesn’t mean that it doesn’t work. This well-designed RCT could be an important step in addressing western skepticism surrounding TCM and reaping the benefits of its holistic effects.

Indeed, the adoption of YPF in RRTI treatment could benefit thousands of children worldwide, and especially those from lower socioeconomic backgrounds. YPF could be one among a line of TCMs gaining worldwide recognition for their treatment benefits, crossing out the “pseudo” while focusing on the “science.” 





Authors: Baoping Xu1, Xinmin Li2, Siyuan Hu2, Yixiao Bao3, Fengmei Chen4, Zhimin Chen5, Yonggang Du6, Enmei Liu7, Yufeng Liu8, Qinghui Mou9, Baoling Su10, Bo Wang4, Jianwen Xu11, Guiping Xu12, Qiaozhi Yang13, Liwei Gao1, Xiaohui Liu14, Lei Li15, Rong Ma2, Kunling Shen1


1 China National Clinical Research Center of Respiratory Diseases, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, China

2 The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, China

3 Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China

4 Guangdong Women and Children Hospital and Health Institute, Guangzhou, China

5 Children’s Hospital of Zhejiang University School of Medicine, China

6 Changzhi People’s Hospital, China

7 Children’s Hospital of Chongqing Medical University, China

8 The Fourth Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, China

9 Qilu Children’s Hospital of Shandong University, China

10 Heji Hospital Affiliated to Changzhi Medical College, China

11 The Third Affiliated Hospital of Xinxiang Medical College, China

12 Huizhou Traditional Chinese Medicine Hospital, China

13 Liaocheng People’s Hospital, China

14 Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, China


About Professor Kunling Shen

Professor Kunling Shen is a Professor at Beijing Children’s Hospital and the Chief of the China National Clinical Research Center for Respiratory Diseases. Her research interests lie in respiratory medicine, virology, and sleep science, and she has published more than 100 books and papers on these topics. She has served as the President of the Asian Society for Pediatric Research and the Society of Pediatrics of the Chinese Medical Association. Prof. Shen is a standing committee member of the International Pediatric Association and a foreign academician of the Russian Academy of Sciences.


About Professor Rong Ma

Professor Rong Ma is a Professor at the Pediatric Department at The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, China. His research interests lie in the treatment of neurologic and pulmonary disease in children with traditional Chinese medicine. He has served as the President of the Branch of Pediatrics, China Association of Chinese Medicine and is Vice President of the Committee of Experts on Pediatric Rational Drug Use of the National Health Commission of China.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.